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CObjectives: The sustainability of national health insurance in South
Korea has been under threat because of the relative and absolute high
expenditure on drugs and its fast rate of increase. According to this
need, a Drug Expenditure Rationalization Plan (DERP) was enacted in
late 2006, and a reevaluation project to delist drugs started in 2007 as
one part of the DERP. Method: This article follows the process of the
elisting policy in Korea. It addresses the history of the policy imple-
entation and its changes, content, and impact and suggests a more
easonable policy direction, thereby setting a helpful example for other
ountries. Results: After a pilot reevaluation and the subsequent eval-
ation of a hypertension drug, the DERP fell into arrears as regards its
riginal time linemainly because of the difficulties in developingmeth-
dologies and the government’s inexperience in managing a megas-
ale reevaluation project. The confusion and conflicts during the eval-
ation became amajor burden on the government and society. Finally, O
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doi:10.1016/j.jval.2011.08.1738he government changed the framework of the delisting policy from
eevaluation based on cost-effectiveness to across-the-board price re-
uctions aiming at the quick attainment of financial savings and min-
mizing conflict between the government and stakeholders.
onclusions: The government should lead the project with a more
onsistent and sustainable assessment framework of cost-effective-
ess as the tool for the rational allocation of health resources, provid-
ng strong leadership and political will and a far-sighted view rather
han focusing on compromise with special interest groups. In addition,
evelopment of more practical and multidimensional evaluation
ethodology is needed.
eywords: delisting policy, drug price, drug reimbursement.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
Rising drug costs in Korea
According to the Organization for Economic Co-operation and De-
velopment’s (OECD’s) health data, in 2005, before a Drug Expendi-
ture Rationalization Plan (DERP) was started in Korea, the propor-
tion of drug expenditure to total medical expenditure was 29.2%,
reaching 7.2 trillion Korean won (approximately US $6.4 billion or
€4.5 billion), which was much higher than the average level of
17.2% for OECD countries [1,2]. In addition, its growth rate was
ore than twice the OECD average level of 6.1%, threatening the
ustainability of health insurance finance. There are many factors
elated to this financial instability of health insurance in Korea,
ith one of themajor factors being the unnecessary and excessive
isting for the reimbursement and use of drugs [3].
Korean health insurance is a single-payer system (National
ealth Insurance Corporation) andmandates health insurance for
ll. The major financial resources are health insurance premiums
hat are levied separately from taxes, with a small portion subsi-
ized from national revenue. Resources for pharmaceuticals are
ncluded in insurance finance, although they are not fixed as a
ertain proportion. Before a positive list systemwas introduced in
006, therewas anegative list system inwhich almost all the drugs
ere listed automatically after being approved by Korea Food and
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1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.rugs Administration and prices of drugs were determined with-
ut considering cost-effectiveness. As a result, the number of
isted drug items reached 20,564 as of February 2005, and this neg-
tive list system was recognized as a major reason behind the
ramatic increase in drug expenditures [4].
Thus, the Ministry of Health and Welfare (MOHW), a govern-
ental agency responsible for health-care and social welfare
olicies, started to seek a rational means to stabilize the health
nsurance budget. Furthermore, legally qualified civic groups
hat participate in decisionmaking regarding health-care policy
lso had a common opinion and requested the establishment of
drug price control mechanism, including reform of the drug
ricing system and reorganization of the drugs listed for reim-
ursement. Finally, the government introduced the DERP in De-
ember 2006.
Establishment of the DERP
Although there were controversies during the Free Trade Agree-
ment (an agreement that removes all trade barriers for the free
flow of products between countries) negotiation, because of a
conflict between the United States, which sought to secure the
minimum drug price, and Korea, which sought to continue with
the DERP, the DERP was enacted before the establishment of the
Free Trade Agreement. The details of the DERP are given in
Table 1. Among the DERP stipulations, the implementation of a
ort.
u, Seoul 110-744, South Korea.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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205V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2positive list system was the first to be undertaken in 2007 [5].
ew drugs began to be listed for reimbursement after economic
valuations and price negotiations, and a plan for the reevalu-
tion of listed drugs according to an economic evaluation was
nnounced in 2007.
First, among 20,564 items listed as of February 2005, about 4000
tems that had never been produced or prescribed since their list-
ng were delisted. The remaining, about 16,000 items, became the
arget of reevaluation.
Although there were several early controversies surrounding
he new drug listing system according to an economic evaluation,
uch as the lack of local clinical data and/or long-term outcomes
ata, the system eventually gained some stability [6]. In contrast,
he reevaluation of listed drugs has not gone smoothly because of
onflicts among stakeholders, including consumer groups, payer
roups, subscriber groups, civic groups, and pharmaceutical com-
anies, and the government’s inexperience in megaproject man-
gement.
In the Korean context, a reevaluation for listed drugs is a prac-
ical policy instrument that can greatly contribute to the rational-
zation of drug expenditures. In addition, its impact would be sub-
tantial because it would affect the listing and prices of new drugs,
s the listed drugs may become the comparators for new drugs in
he economic evaluation.
The purpose of this article was to review the decision-making
rocess, implementation, and implications of the Korean delisting
olicy and suggest various recommendations, thereby setting a
ood example for other countries that may be considering a del-
sting policy.
Reevaluation of Listed Drugs
Original plan
The initial reevaluation plan for listed drugs announced in 2007 by
the MOHW started with a pilot evaluation of hyperlipidemia and
Table 1 – Drug Expenditure Rationalization Plan.
1. Introduction of a positive list system and drug price negotiation s
● List new drugs evaluated as superior therapeutically and econ
● Introduce a negotiation process for new drug pricing between
Corporation.
● Fix generic drug prices at a certain percentage of the price of a
● Reorganize the drugs listed before the DERP enforcement: ana
years from 2007 to 2011 and delist or adjust the prices of non–
2. Management of drug price listed for reimbursement
● Adjust drug prices with expired patents when the first generic
● Adjust drug prices through renegotiation if sales exceed the v
extended.
● Give economic incentives to medical institutions purchasing d
3. Management of drug utilization
● Reduce the volume of prescriptions with the cooperation of m
● Tighten up assessments regarding the proper use of drugs.
– Extend the assessment scope, including the prescription rat
prescriptions, and the drug cost per medication day, and op
– Monitor institutions prescribing drugs excessively, reinforce
consider financial incentives.
4. Improvement of drug quality and transparency in distribution ch
● Increase the reliability of bioequivalence tests of generic drug
● Improve the management of product quality and control the m
● Strengthen follow-up testing of drugs: Cancel the approval of
supposed to submit regularly are not submitted after approva
● Build a system for accumulating and analyzing information ab
● Upgrade the drug bar code system and use an electronic card
distribution of drugs and making the drug trade transparent.
* Korea Good Manufacturing Practice: Regulation for quality assuranmigraine drugs [7,8]. These two efficacy groups were selected for the pilot evaluation based on precedents in other countries and
ecause they minimize the confusion of the reimbursement drug
ist because they are not for the treatment of acute and severe
iseases and have neither too big nor too small a market share.
his was followed by a formal evaluation involving six efficacy
roups, including hypertension drugs, in 2008 [9]. Last, the contin-
ous evaluations for 49 efficacy groups were scheduled for com-
letion by 2011. The efficacy group was classified on the basis of
onsultation with medical professions and review of literature by
he Health Insurance Review and Assessment Service (HIRA), a
overnmental agency for reviewing the adequacy of claims from
edical institutions and supporting various tasks related to
ealth-care management that the government performs. Prioriti-
ation of evaluation of 49 efficacy groupswas based on the amount
laimed for reimbursement and expert opinions [9]. The MOHW
overned the overall project, and HIRA was engaged at a working
evel.
The decision-making process in a pilot evaluation is shown in
igure 1. In this process, after the MOHW announces the evalua-
ion target groups, HIRA reviews the documents submitted by
harmaceutical companies, evaluates the clinical usefulness, and
erforms cost-effectiveness analyses of the drugs independently
f the data submitted by the pharmaceutical companies. While
his process had been carried out by HIRA in the pilot evaluation,
he formal evaluation projects were performed by independent
esearch teams in academia selected through competition. Then,
fter passing through a process in which pharmaceutical compa-
ies can give their opinions about the evaluation results, the Drug
eimbursement Evaluation Committee (DREC), the consultative
ody established inHIRA thatmakes decisions regarding newdrug
istings as well as prices of new health technology, reviews the
esult. Finally, the Health Insurance Policy Review Committee
HIPRC) of theMOHW, an affiliated organization set up for decision
aking as regards important health insurance policies, confirms
nd announces the overall results, such as the drugs to be del-
sted/retained on the reimbursement list [10] (Table 2). Although
ally only to maximize cost-effectiveness.
maceutical companies and the National Health Insurance
ly negotiated drug with the same ingredients.
he cost-effectiveness of drugs according to efficacy groups for 5
effective drugs.
with the same ingredients is listed.
e agreed upon in advance or if reimbursement scopes are
at lower prices in the transparent route.
l professionals.
certain period of time, the proportion of expensive drugs among
e assessment results to the public.
ation of medical professionals about proper drug use, and
ls
expand test targets.
facturing facilities adequately through the KGMP*.
if bioequivalence data that pharmaceutical companies are
roduction and supply systematically.
ated for drug purchases for the efficient management of the
ch as efficacy, safety, and stability from manufacturing to sales.ystem
omic
phar
new
lyze t
cost-
drug
olum
rugs
edica
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en th
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anu
drugs
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dediche pilot evaluation greatly lagged behind its planned schedule
206 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2because of strong opposition from relevant stakeholders with a
largemarket size of hyperlipidemia drugs, 4 items among 321were
delisted and the prices of 124 itemswere reduced by 15.2% accord-
ing to the evaluation results.
In the hypertension drug evaluation process that com-
menced in July 2009, the specific framework of the reevaluation
procedure that could be applied to other efficacy groups in the
future was developed on the basis of lessons from the pilot
evaluation and a discussion involving the MOHW, HIRA, medi-
cal professions, pharmaceutical industry, and those in related
academia (Fig. 2).
First, essential drugs including ban-on-delisting drugs, or-
phan drugs, emergency drugs, and drugs without any alterna-
tives are to remain on the reimbursement list without any con-
sideration of their effectiveness or cost. Ban-on-delisting drugs
are low-priced but indispensable drugs designated by the
MOHW for the purpose of preventing pharmaceutical compa-
nies from halting their supply because of the nonprofitability of
their production. Orphan drugs are drugs for diseases afflicting
fewer than 20,000 patients and for which no other proper treat-
ments or alternative medicines exist.
In the second step, drugs are categorized into two groups—
major and minor disease drugs—on the basis of the relative
prevalence rate, the social burden, and the impact of the disease
Fig. 1 – Decision-making process of the reevaluation
project.
Table 2 – The organization of the Health Insurance Policy R
Chairman (one person, by ex officio) ● Vice minister of Health
Committee members (24 persons, by
appointment or request)
● Representatives from s
(FKTU), Korea Confede
Federation of Small an
Korea Federation of Co
(KAFF), and Korea Rest
● Representatives from p
Association (KMA), Kor
Association of Korean
Pharmaceutical Associ
● Representatives from p
Ministry of Strategy an
Insurance Review and
Subcommittee
Chairman (one person, by ex officio) ● Researcher from the K
Committee members (eight persons) ● Three subscribers, three proon the insurance budget. Minor disease drugs can remain on the
reimbursement list regardless of the cost once they are recog-
nized as clinically useful, because the number of drug items for
minor diseases is very small and they cannot be compared with
major disease drugs by the same indicators, whereas major dis-
ease drugs are subject to subsequent steps. For example, there
are two disease codes in hypertension: general hypertension
and pulmonary hypertension. Of the two, general hypertension,
which is more burdensome socially and accounts for a larger
part of the health insurance budget, was designated as a major
disease. Hence, pulmonary hypertension drugs are evaluated
only in terms of their clinical usefulness, and general hyperten-
sion drugs are evaluated in terms of both their clinical useful-
ness and cost-effectiveness.
Drugs having more than two indications are evaluated in the
efficacy groups into which they fall. However, a price reduction is
applied a maximum of two times. In other words, if a drug having
three indications of hypertension, heart failure, and renal failure
was evaluated two times for hypertension and heart failure effi-
cacy groups and its price was reduced two times according to the
results of those evaluations, it would not be evaluated as part of
the renal failure efficacy group.
The evaluation criteria for clinical usefulness are shown in Ta-
ble 3. Drugs are considered as clinically useful if theymeet any one
of the three requirements in grade A, such as a reference in a
textbook, a recommendation in clinical practice guidelines, or a
listing on the World Health Organization list of essential medi-
cines. If none of the grade A requirements is met, all of the three
requirements in grade B have to bemet for a drug to be recognized
as clinically useful, that is, a recommendation by related aca-
demia, special merits recognized by the DREC, and current usage
in the countries grouped under the rubric “advanced 7 countries”:
United States, United Kingdom, Germany, France, Switzerland, It-
aly, and Japan. Drugs lacking clinical usefulness that are rejected
in both grade A and grade B are delisted, whereas the others pro-
ceed to the next step.
Next, alternative groups within which each drug can be substi-
tuted with each other are set, and the daily costs of the drugs
estimated from the unit price and daily dose are compared within
the alternative groups. If the daily cost of a certain drug belongs to
the bottom 25%, which is a criterion arbitrarily determined by the
government, the drug is recognized as a relatively low-price drug
and can stay on the reimbursement list without an additional eco-
nomic evaluation. The rest of the drugs are evaluated in terms of
their cost-effectiveness. In this evaluation, if the drugs are judged
to be similar in terms of clinical effectiveness, a cost-minimization
analysis is performed. If not, a cost-effectiveness or cost-utility
analysis is done [11].
w Committee (December 31, 2009) and Subcommittee.
Welfare
riber groups (eight persons): Federation of Korean Trade Union
of Trade Unions (KCTU), Korea Employers Federation (KEF), Korea
ium Business (KFSMB), Citizens United for Better Society (CUBS),
er Organization (KFCO), Korea Advanced Farmers Federation
t Association (KRA)
ers (eight persons, two of whom are from KMA): Korean Medical
ospital Association (KHA), Korean Dental Association (KDA), The
tal Medicine (AKOM), Korean Nurses Association (KNA), Korean
(KPA), Korea Pharmaceutical Manufacturers Association (KPMA)
institutions (eight persons): Ministry of Health and Welfare,
ance, National Health Insurance Corporation (NHIC), Health
sment Service (HIRA), and four other experts from academia
nstitution for Health and Social Affairs (KIHASA)evie
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207V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2In the reevaluation of hypertension drugs, only 1 among 1226
items was delisted because of lack of clinical usefulness. In the
evaluation of clinical effectiveness, not all hypertension drugs are
clearly different in terms of proxy outcomes (systolic blood pres-
sure, diastolic blood pressure) and final outcomes (all-cause mor-
tality, cardiovascular mortality, cardiovascular morbidity). There-
fore, the prices of hypertension drugs would have to be reduced to
the lowest level if a cost-minimization principle is applied. It can
be, however, problematic to select the lowest price as the refer-
ence price. First of all, the value of drugs does not correspond to
the price because their price was set without strict criteria before
the positive list system. Second, because drugs newly introduced
for reimbursement cannot be listed at a price higher than those of
already listed drugswith the same ingredients in Korea, local com-
panies have emerged to deter rival companies from entering the
market; local companies list drugs for reimbursement, which they
have no intention of selling, at a very low price. For these reasons,
the reference price was suggested as a band rather than a fixed
price in hypertension drug evaluation. However, it became invalid
after all because the delisting policy was changed to an “across-
the-board” plan.
Fig. 2 – Reevaluation fr
Table 3 – Clinical usefulness criteria for major disease drug
Criteria
Grade A Textbook, guideline, WHO list Œ Textbook
– Check ref
textbook
Œ Clinical pra
– Check the
ŒWHO list fo
(http://www
essentialme
Grade B Recommendation by academia Œ Essential dr
academic s
Recognition of specialty by the DREC Œ Special cha
DREC)
Usage in foreign countries Œ Listing in m
countries (U
Germany, FA7, advanced 7; DREC, Drug Reimbursement Evaluation Committee; WHOBarriers in the process
As mentioned previously, the pilot evaluation and subsequent
evaluations were delayed much more than planned, revealing
many problems [7,8]. The problems most frequently raised by
pharmaceutical companies were the transparency of the evalua-
tion process, the evaluation methodology, and the serious impact
on the pharmaceutical industry due to price reduction.
It is true that there were some unclear parts in the process,
such as the selection of DRECmembers by ambiguous criteria and
keeping themeetingminutes confidential. The composition of the
DRECmembership made it difficult for the opinions of consumers
to be reflected fully. In addition, scientific disputes among stake-
holders continued even after the end of the evaluation. In the
hypertension drug evaluation, which ended in February of 2010,
there was an opportunity in March of 2010 for relevant interest
groups to appeal the evaluation results, and numerous objections
about the selection of target patient, classification of an alterna-
tive group, and analysis method were raised. The interest group
even went so far as to request a reevaluation of hypertension
drugs by other researchers. To these stakeholders’ claims, how-
work for listed drugs.
Details Decision
Drugs meeting any one of the
e or recommendation in a three: “clinically useful”
guideline
mmendation level
ential ingredients
.int/medicines/publications/
es/en/index.html)
or treatment (opinions of
es)
Drugs meeting all three:
“clinically useful”
ristics of drugs (reviewed by the
han two countries among A7
States, United Kingdom,
, Switzerland, Italy, and Japan)ames.
erenc
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rance, World Health Organization.
208 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2ever, the government adopted a non-neutral attitude and was bi-
ased toward the opinions of the pharmaceutical industry, holding
two unscheduled hearings and a panel discussion only for the
pharmaceutical industry. It even deviated from the determined
process, such as extending the appeal period from30 to 60 days. As
a result, the actual price reduction for hyperlipidemia drugs was
not implemented until March of 2009, the hypertension drug eval-
uation planned for 2008 did not begin until July of 2009, and the
evaluation of drugs in the five efficacy groups also planned for
2008 did not start until November of 2009. None of the evaluations
proceeded in time according to the original schedule.
In fact, the dominant view from the beginning was that the
on-schedule reevaluation would be impossible because of the na-
ture of the system. First, the economic evaluation itself is a time-
consuming job. It is almost impossible to conduct the reevaluation
comparing long-term outcomes of all drugs of one efficacy group
within 1 year, especially in the case of drugs for chronic disease.
Second, the infrastructure for the implementation of large-scale
economic evaluations in Korea was insufficient.
The government judged from the two previous experiences
(i.e., hyperlipidemia and hypertension drug evaluations) that find-
ing a methodology with which all interest groups could agree was
impossible, and if a reevaluation project is implemented at such a
speed, it would not be finalized until 2020, making budget-saving
claims dubious. In addition, the Ministry of Strategy and Finance
strongly requested an across-the-board price reduction to save the
national health insurance from financial deficit as soon as possi-
ble.
Eventually, the evaluation framework was changed totally
from an economic evaluation to an across-the-board price reduc-
tion so as to finish the reevaluation project for listed drugs as soon
as possible and remove the administrative burden placed on all
stakeholders and on the government.
Change from an Economic Evaluation to an Across-
the-Board Price Reduction
Amendments
The government suggested an “across-the-board price reduction”
Table 4 – Government’s amendments for a reevaluation of
1. Price adjustment
● First, drugs with insufficient clinical usefulness will be exclud
● In the next step, relatively low-price drugs belonging to botto
a reevaluation process.
● Among drugs not belonging to the low-price drugs category, d
medicines (drug groups with the same ingredients, type, and
pharmaceutical company reduces the drug’s price voluntarily
drug can be retained on the reimbursement list. This 80% lev
system, the original drug listed after the introduction of the D
with the same ingredients is listed. Because the targets of the
of the DERP, this will ensure no discrimination between drug
identical medicines is lower than the relatively low-price crit
2. Target of reevaluation
● The reevaluation targets are original drugs for which generic
before the DERP enforcement (excluding essential drugs such
drugs listed within the group of identical medicines before th
evaluated as soon as the patent expires. In addition, drugs lis
expired.
● Although a drug was listed before the DERP enforcement, if it
drug with identical ingredients after the DERP enforcement, t
3. Price reducing method
When a pharmaceutical company voluntarily wants to reduce dr
over 3 years (to the 7% level in the first year, the 14% level in the
DERP, Drug Expenditure Rationalization Plan.plan thatwas verydifferent from the initial plan. Its specific contentsare specified in Table 4 [12]. The biggest alterations from the original
plan were that delisting should be determined mainly not by eco-
nomic evaluations but by the criterion ofmeeting 80% of the highest
priceamongdrugshaving identical ingredients, type, anddose (here-
after referred to as identical medicine). In other words, drugs whose
price was above the 80% level were to be removed from the reim-
bursement list but could be retained if the pharmaceutical company
voluntarily reduced the drug price to 80% or lower; in this case, the
reduction could be spread evenly over 3 years, up to 7%, 14%, and
more than 14% for the first, second, and third years, respectively.
This criterion is not to be applied to the following: essential drugs
(ban-on-delisting drugs and orphan drugs), drugs with valid patent,
incrementally modified drugs without generic drugs, and drugs
listed before the implementation of the DERP, whose price was re-
duced to 80% of the level of the original price because of the listing of
a generic drug, which is also one clause of the DERP.
The rationale for the 80% criterion suggested by the govern-
ment was as follows: The main targets of the delisting policy are
the drugs listed before theDERP, and prices of drugs listed after the
DERP are to be reduced to the 80% level when a generic drug with
the same ingredients is listed for reimbursement. Therefore, the
government viewwas that 80%would be a reasonable criterion for
fairness between drugs listed before and after the DERP.
The government planned to finish the evaluation project of
listed drugs with this changed plan by the latter half of 2011 and
forecasted annual savings of 836.2 billion Korean won (approxi-
mately US $771 million or €543 million) in national health insur-
ance finance. This was the amount calculated assuming that the
drug price reductions for 47 efficacy groups would be applied to
drug expenditures in 2009.
History of decision making in changing plan
On July 16, 2010, an amendment of the reevaluation of listed drugs
was proposed under the name “reevaluation plan of listed drugs”
on the agenda of the HIPRC. This plan was adopted by a majority
of the HIPRC subcommittee on July 20, 2010. On that date, repre-
sentatives from provider groups, subscriber groups, and public
institutions participated in voting. Finally, only the Korea Confed-
eration of Trade Unions (KCTU) refused to agree. The composition
of the HIPRC is shown in Table 2. In the composition scheme, the
d drugs.
om the reimbursement list.
in daily cost will be retained on the reimbursement list without
in the top 20% in daily cost within the group of identical
will be excluded from the reimbursement list. However, if the
e 80% or lower level within the group of identical medicines, the
ased on the rationale of fairness. In other words, in the existing
s required to reduce its price to the 80% level when a generic drug
aluation of listed drugs are those listed before the implementation
d before and after the DERP. If the 80% level within the group of
elatively low-price criteria will be applied.
with the same ingredients are available and that were listed
n-on-delisting drugs, rare drugs, and patented drugs). Second,
P enforcement and those whose patent is still in force shall be
lely as identical medicines shall be included if the patent has
e was reduced to the 80% level because of the listing of a generic
ug shall be excluded from the target list.
ices to 80% or to a lower level, a reduction can be done gradually
d year, and greater than the 14% level in the third year).liste
ed fr
m 33%
rugs
dose)
to th
el is b
ERP i
reev
s liste
eria, r
drugs
as ba
e DER
ted so
s pric
he dr
ug pr
seconvice minister of Health and Welfare automatically becomes the
e Pol
209V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2HIPRC chair, and 24 committee members are composed of repre-
sentatives of eight subscriber groups, eight provider groups, and
eight public institutions.
The KCTU is a consumer-oriented organization that plays a piv-
otal role in the network of civic groups and trade unions. It also ex-
ercises political leverage as a leader of the civic groups, havingmany
supporters and being strongly connectedwith the Democratic Party.
After the changed plan proposed by the government was passed
byamajorityofvotes in thesubcommittee,despiteKCTU’sobjection,
theKCTUdiscussed this issuewithcivic groups through twourgently
arranged conferences and submitted an independent plan on July 22
that was different from the government’s plan (Table 5). The plan
suggested jointly by the KCTU and the civic groups clearly stated
their objection to the government’s plan inprinciple. They requested
delisting the drugs that did not satisfy the reimbursement criteria
rather than allowing price reduction, and applying price reduction
regardless of patent validity, and all at once rather than in phases, if
at all. In addition, they asked the government to present evidence
supporting its estimation that the government’s amendments could
achieve savings of 836.2 billion Koran won (US $771 million or €543
million) in health insurance finance. Both the plan proposed by the
government and the KCTU/civic groups plan were referred to the
HIPRC plenary meeting held on July 28, 2010. Finally, the govern-
ment’s plan was put to the vote and passed.
Eventually, the changed plan was applied to hypertension
drugs, the second efficacy group in the reevaluation project of
the listed drug on which no political action had taken place
since the completion of the evaluation study, and its price cut
was implemented in January of 2011. The evaluation studies for
five efficacy groups that had been in progress since the begin-
ning in November of 2009 also ended uncompleted in August of
2010. The government had an action schedule to cut the price of
these five efficacy groups in July of 2011, and the price of the
remaining 41 efficacy groups by January of 2011 according to the
changed plan.
Responses from stakeholders
Pharmaceutical industry
It is expected that the changed plan may cause serious damage to
middle- and high-ranking domestic pharmaceutical companies as
well as major multinational ones, more so than it will impact
smaller companies. Although the government suggested the goal
Table 5 – Plans proposed by the government and by subsc
Government’s plan (majority opin
subcommittee)
Decision criteria ● Same as Table 4.
Reevaluation target ● Drugs listed before the DERP enforcemen
generic drugs of the same ingredients list
Exempted from
reevaluation
● Essential drugs (ban-on-delisting drugs, r
etc.).
● Drugs with valid patent (including increm
modified drugs).
● Drugs whose price is reduced to the 80% l
of generic listing after the DERP enforcem
Time line
DERP, Drug Expenditure Rationalization Plan; HIPRC, Health Insurancof fairer pricing between drugs listed before and after the DERP asa rationale for the criterion of the 80% price level, the prices of
many drugs listed before the DERP were already lowered several
times because of other systems, such as 1) the drug price readjust-
ment system that readjusts drug prices triennially to reflect
changes in drug price in advanced 7 countries and 2) the drug price
monitoring system that investigates the actual transaction price
three or four times every year and reduces the drug prices to the
actual price level [13]. In some cases, more than half of the price
may be reduced if both the price readjustment system and the
reevaluation system of listed drugs are applied. Therefore, phar-
maceutical companies have insisted that it would bemore reason-
able to apply a 20% price reduction not on the current price but on
the initially listed price.
In fact, opinions even within multinational pharmaceutical
companies have been varied [14]. Some companies have argued
that there is no justification or reason to accept the across-the-
board price reduction, insisting that they only wanted to retry the
hypertension drug evaluation by using other methodology rather
than denying the economic evaluation principle completely. Some
companies supported the newly changed plan even though it was
not fully satisfactory. Other pharmaceutical companies did not
take a clear stance, saying that a precise estimation of profit and
loss is required because the evaluations of some efficacy groups
that in the original plan had been planned for 2012 or later were
moved forward to 2011 in the changed plan.
There were also differing opinions among domestic pharma-
ceutical companies. They, however, converged toward the opinion
that it seems to be better to accept the plan, because its impact
would bemuch less than that of the original plan, given that prices
of hyperlipidemia drugswere reduced by amaximumof 37.5% and
that hypertension drug prices should be reduced by amaximumof
80% according to the cost-minimization principle.
Taken as a whole, the pharmaceutical industry seemed not
to oppose the across-the-board price reduction plan because it
would be much less severe and would, in fact, decrease the
burden on the company considerably [15]. A simulation analysis
with the top 100 most frequently prescribed hypertension drugs
showed that only 26 products were subjected to a price reduc-
tion by the government’s changed plan and that most drugs in
the angiotensin receptor blocker or angiotensin-converting en-
zyme inhibitor class with the highest prices among hyperten-
sion drugs were excluded because most of them have valid pat-
groups.
f KCTU (joint opinion with civic groups)
● Object to the government’s plan.
● Request detailed evidence about the cost-savings
effect in insurance finance.
● Request for abiding by HIPRC decisions made in
2009 (delisting drugs not satisfying the
reimbursement criteria, not offering an opportunity
for a price reduction, and a price reduction done at
once, not over 3 years).
● Identical to the government’s plan.
rugs, ● Apply a price reduction regardless of the validity of
a patent.
lly ● Clarify the reevaluation schedule and start plan as
soon as possible.
because
icy Review Committee; KCTU, Korea Confederation of Trade Unions.riber
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The Korean Medical Association expressed its disagreement with
the changed plan, as it did in the pilot reevaluation [16]. It did not,
however, suggest any alternative plan or take any strong action,
only insisting that other methodology needs to be developed be-
cause objectivity and reliability are not guaranteed in an economic
evaluation. It also insisted that if the across-the-board price reduc-
tion is implemented, the portion saved through it should be used
to raise physician fees.
Civic groups
Civic groups expressed their strong objection practically, such as
by submitting a separate proposal together with the KCTU against
the government’s plan.
On July 28, 2010, the day of the HIPRC plenary meeting, they
held a press conference to urge the government to abandon the
changed plan. The reasons for their objectionwere as follows: first,
it severed the agreements based on the experience of the pilot
evaluation, which suggested that the number of drugs listed for
reimbursement, rather than prices, should be reduced and that
lowering the price of the drugs should be done all at one time
rather than in a progressive manner. Second, the cost-saving ef-
fect of the government’s plan was doubtful. Last, giving up reeval-
uation based on economic analysis and turning to across-the-
board price reduction was viewed as being unsustainable and
disconnected with other policies of the DERP [17].
The civic groups also strongly expressed their view that if
the changed plan was enforced without their agreement, they
would resist its implementation by using all available actions,
such as requesting an audit of the MOHW to the Board of Audit
and Inspection, administrative litigation, and requesting open-
ing of the background data on the cost-saving effect of the
changed plan [18]. They focused, however, on accomplishing
their plan later (Table 5), which was proposed jointly with the
KCTU, rather than clinging to an overall objection to the gov-
ernment’s plan, considering that too much persistence on prin-
ciple and cause would attain nothing.
Challenges to the Delisting Policy
Currently, many countries such as Australia and Spain have been
trying to advance disinvestment issues and have put these issues
on their national agenda. As part of this effort, they tried develop-
ing guidelines and identifying key challenges to search for the best
avenues [19–21]. In Australia, five challenges were identified: a
ack of resources; lack of reliable administrative mechanism; lack
f published evidence; political, clinical, and social challenges;
nd inadequate resources to support a research agenda [19]. Some,
but not all, of these problems also exist in Korea. In the delisting
policy of Korea, there were problems such as the lack of a reliable
administrative mechanism and of published evidence studies, as
well as clinical and social challenges, whereas resources for policy
implementation were supported without dispute.
The following key lessons learned from experiencing chal-
lenges can be helpful for other countries (Table 6).
Managerial ability of the government
There were a few reasons that led the government to change the
framework for the reevaluation of listed drugs from cost-effective-
ness to an across-the-board price reduction. The most serious
among them was the delayed schedule of the evaluation project.
The government wanted to alleviate the burden on both the phar-
maceutical companies and themselves by finishing projects via an
across-the-board price reduction and realizing rational drug ex-
penditures as soon as possible. It is true that the delay in the
evaluation schedule was partly due to the nature of the studyitself. The lack of government’s managerial ability, however, was
to blame as well—for example, its excessive consideration for the
stakeholders’ interests. In addition, the evaluation periods were
gradually being shortened based on the experience gained during
the hyperlipidemia and the hypertension drug evaluations. There-
fore, it is assumed that the reevaluation project for the remaining
efficacy groups would have been completed in a much shorter
time compared with the time needed up to that point.
The government also insisted that an across-the-board price
reduction could raise the possibility for concerned interested par-
ties to predict the impact of the policy andmake it easier to comply
with it. In other words, in an economic evaluation, it was difficult
for a pharmaceutical company to predict the result of an analysis
and adjust its drug price in advance so as not to have the drug
delisted from reimbursement. It is certain that pharmaceutical
companies, however, would always respond negatively to any re-
evaluationmethod because the reevaluation itself would certainly
not increase their profit. In addition, because the original purpose
of the reevaluation for the listed drugs was to reduce the number
of listed drugs rather than lower the prices, making it easier for a
pharmaceutical company to predict the result of an evaluation
and giving it a chance to reduce its drug price so as not to be
dropped out of the reimbursement list would be at odds with the
original purpose of the reevaluation project.
The government’s leadership and strong will are very impor-
tant for the successful implementation of a policy. In fact, in the
implementation of the delisting policy, it seemed that the aware-
ness of the crisis in health insurance finance and the necessity of
drug expenditure control were raised sufficiently, and agenda set-
ting such as a delisting policy and a positive listing system for new
drugs was proper. The government, however, showed a lack of
managerial ability, and its will was weakened in the actual imple-
mentation step, partly because of the conservative political ideol-
ogy of the ruling party. In addition, there was no strong network
among groups advocating the policy. If the government had han-
dled this challenge more intelligently and decisively with a reli-
able administrative mechanism, a sustainable framework for a
delisting policy applicable in the future may have been estab-
lished.
Methodology of the delisting policy
The government’s changed plan compares the costs only within
drugs having an identical type, ingredient, and dose (i.e., identical
medicine), whereas an economic evaluation compares both the
effectiveness and the cost of all the drugs in the same efficacy
group. In the evaluation of the hypertension drugs, drugs within
the same classes such as beta-blockers and angiotensin receptor
blockerswere first comparedwith each other in terms of effective-
Table 6 – Key lessons for other countries.
1. Policymakers and executors need to clearly recognize the
objective of policy and the function of its tool. In the
reevaluation of the listed drugs, they should have realized that
economic evaluation is not merely for price reduction but for
rational drug expenditure.
2. The policy tool should be sustainable and rational and can be
publicly supported. In addition, it should be practical, which
means that it cannot be too academic or scientific and should
be easy to implement.
3. Balance between harmonization with stakeholders and sticking
to the principle is very important especially when policy is
involved with many interest groups.
4. It is better for policy to be incremental, considering the
experiences of past policies.
5. Policy should be based on evidence that is as precise and
detailed as possible.ness. After it was concluded that therewere no clear differences in
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in effectiveness between the classes was evaluated. In this man-
ner, all the drugs indicated for hypertension were compared with
each other. Althoughdrugs deficient in clinical usefulness are sup-
posed to be delisted regardless of their cost in the first step in the
across-the-board price reduction also, it can be said that the
changed plan is mainly focused on cost rather than on clinical
effectiveness, as the number of excluded items in the clinical use-
fulness reviewphasewould be extremely small, given the fact that
in the hypertension drug evaluations, only 1 item among 1226
items was delisted because of the lack of clinical usefulness.
In addition, the across-the-board price reduction scheme is not
consistent with the current new drug listing system. Since the
introduction of the positive list system, the listing and pricing of a
new drug is based on cost-effectiveness analysis, and a compara-
tor in the economic evaluation is selected not onlywithin identical
medicines but also within all possible scope, including even non-
intervention options.
Of course, there may be a need for such a mechanical price
reduction in the early stages of evaluation. However, relying on an
across-the-board price reduction scheme as the onlymethodology
would be risky and will eventually lose its overall consistency as a
standard for drug reimbursement.
A delisting policy based on economic evaluations should be the
priority instead of annulling all the studies underway and detour-
ing toward poorly grounded, across-the-board price reductions
merely for convenience and for time considerations. It is impor-
tant to construct a basic frame based on reliable theory andmeth-
odology that can be used for a long time, because health insurance
itself is not merely a short-term system. Considering the context
in Korea, where a considerable number of drugs are already listed
compared with the number in other countries, an economic eval-
uation for listed drugs needs to be designed somewhat simply and
feasibly for practical application to policy, unlike that for the list-
ing of a new drug.
Competitiveness of local pharmaceutical companies in the
international market
Korean pharmaceutical companies tend to focus on the produc-
tion, distribution, and sales of generic drugs rather than develop-
ing new drugs on their own through research and development. In
addition, it is commonly recognized that the negative list system
has been deteriorating the competitiveness of local companies in
the international market. Local companies could enjoy a good
profit for a long time because they could list their drug for reim-
bursement very easily and obtain high prices relative to their pro-
duction cost under the negative list system. Rather than investing
in research and development to improve drug quality or develop
new drugs, however, many companies spent part of this profit on
unethical promotion intended to induce prescription of their
products [22,23]. According to a press release of the Fair Trade
Commission, a central administrative organization under the au-
thority of the prime minister, as much as 20% of the total sales of
local companies were estimated to have been spent on this type of
promotion [24].
In the government’s changed plan, it is assumed that generic
drugs have little impact because most drugs belonging to the top
80% groups are original drugs. For this reason, a delisting policy
based on a cost-effectiveness analysis could be an effective instru-
ment to enhance the quality and competitiveness of local produc-
ers by giving themopportunities to change their business behavior
in the market. The government, however, gave up this chance by
changing the plan.Public support for the government policy
Subscriber groups and civic groups recognized the government’s
decision to forego the original delisting policy as a stereotype of
the so-called capture theory in policy-making and became much
less supportive of the government’s health-care policy thereafter.
The opposition party in the National Assembly discussed this is-
sue in a public conference and criticized the government’s inabil-
ity to implement the policy. The Korean national TV network
broadcast a program about the delisting policy in January of 2011
and pointed out the government’s failure in a pharmaceutical pol-
icy. The Korean Association of Health Technology Assessment
held a conference regarding the delisting policy and opened the
debate to pros and cons. Through a series of discussions, the gov-
ernment seemed to lose public support and reliability, which has
made the government’s leadership less effective.
Conclusions
South Korea is the first country in Asia to develop a pharmacoeco-
nomic evaluation guideline and apply cost-effectiveness criteria
to reimbursement decision making through pharmaceutical pol-
icy reform. Therefore, we have experiencedmany trials and errors
and have many issues to be addressed, such as the lack of domes-
tic clinical data, restrictions in accessibility to cost data, and the
noncompliance of stakeholders.
While a new drug listing system has been established in spite
of these difficulties, the delisting policy has not gone smoothly.
Much resistance has been expressed by stakeholders, and the gov-
ernment did not cope well with these issues. Eventually, it turned
to an across-the-board price reduction plan, annulling all the eval-
uation studies in progress. The pharmaceutical policy reform in
South Korea failed in that it was abandoned even before being
properly implemented, and the policy changed by the government
is not expected to have a significant cost-saving impact on the
health insurance budget, not giving any motivation to local com-
panies to strengthen their competitiveness.
If an attempt is made to identify a few opportunities and real-
ize them, however, there is still the potential for financial savings
through a delisting policy. First, the government needs to imple-
ment a drugs delisting policy with a wide and far-sighted scope,
rather than focusing only on visible short-term performance. To
do this, it is rational to conduct a policy under an economic eval-
uation principle. The concept of cost-effectiveness would be well
founded and sound as a tool for the delisting policy in spite of its
limitations and difficulties, as long as its methodology is designed
more practically. Second, if the ultimate purpose of the delisting
policy is financial savings through drug price reductions or by
downsizing the reimbursement drug list, a policy tool for such a
purpose should be operated separately from an economic evalua-
tion. Economic evaluations are not a tool for merely reducing the
budget but for allocating health resources efficiently. It is undeni-
able that all the confusion was caused because of the distorted
understanding of an economic evaluation by those concerned, in-
cluding government officials, because the positive list system us-
ing economic evaluations was introduced at the time when the
deficit in the insurance budget was a major issue, with excessive
drug expenditures blamed for it. Finally, a methodology based on
economic evaluations for drug pricing should be designed from a
greater number and variety of angles, that is, reflection of an eq-
uity factor that lacks in economic evaluations and social accept-
ability.
In 2010, the Korean national health insurance showed the larg-
est deficit ever, reaching approximately 1.3 trillion Korean won
(approximately US $1.2 billion or €844 million). Uncontrolled drug
expenditures due to the failed delisting policy is one of the factors
for this crisis. This could, however, actually present opportunities
[[
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212 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 0 4 – 2 1 2for reconsidering the delisting policy, because this crisis creates
further pressure for drug expenditure containment, finally leading
to the stable management of health insurance finance if all the
opportunities explained previously are realized together.
Source of financial support: The authors have no other finan-
cial relationships to disclose.
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